I
nflammation is the body's physiologic response to disturbance caused by infection, trauma, or injury. The onset and perpetuation of inflammation involve a complex network of cytokines, such as tumor necrosis factor (TNF)-␣, interleukin (IL)-1, IL-6, and high mobility group box 1 protein, causing up-regulation of controlling transcription factors, such as nuclear factor (NF)-B (1, 2). Unbalanced overproduction of these mediators provokes overwhelming reactions resulting in systemic inflammation and eventually lethal multiorgan failure (3) . Neutralization of TNF-␣ or high mobility group box 1 protein by monoclonal antibodies has been shown to confer resistance to bacteremic septic shock in animal models of sepsis in accordance with the pivotal role of proinflammatory cytokines in the promotion of the systemic inflammatory responses (4, 5) .
Recently, the so-called "cholinergic anti-inflammatory pathway" has been described as a mechanism for neuronal control of inflammation via the efferent vagus nerve (6 -8) . Acetylcholine, the principal parasympathetic neurotransmitter, attenuates the release of cytokines from lipopolysaccharide-activated macrophages in vitro, and electrical stimulation of the vagus nerve protects against septic shock in experimental bacteremia in vivo (8, 9) . Wang et al. (10) showed that acetylcholine inhibits TNF-␣ release from macrophages via the ␣7 nicotinic acetylcholine receptor (nAChR). The release of high mobility group box 1 protein from macrophages (11) and endothelial cell activation (12) are also suppressed by nicotinic parasympathetic signaling via the ␣7 nAChR and by the subsequent inhibition of the NF-B pathway via decreased transactivation activity of the transcription factor.
In an effort to employ the knowledge of the cholinergic anti-inflammatory pathway, many groups have studied animal models of inflammation and have shown beneficial effects by direct electrical stimulation of the vagus nerve (9, (12) (13) (14) , treatment with nicotine (11, 15) or other nicotinic agonists (12, 16, 17) , pharmacologic activation of central muscarinic M1 acetylcholine receptors (18) , or direct pharmacologic stimulation of vagus nerve firing (14) .
Cholinergic activation by means of cholinesterase inhibition is already being used clinically, for example, in the treatment of the central anticholinergic syndrome or as an adjuvant in pain therapy (19) . In this study we tried to pharmacologically activate the cholinergic antiinflammatory pathway in a way that could also be used in patients.
METHODS
Reagents. Physostigmine was purchased from Köhler Chemie (Alsbach-Hähnlein, Germany), neostigmine from Delta Select (Pfullingen, Germany), and nicotine from SigmaAldrich (Munich, Germany).
Cecal Ligation and Puncture (CLP). CLP was performed as described previously (20 -23) after approval by the appropriate local review committee and in compliance with governmental guidelines. In brief, female C57BL/6 mice aged 12-16 wks were anesthetized by intraperitoneal administration of 75 mg/kg Ketanest (Ketamine, Pfizer Pharma, Karlsruhe, Germany) and 16 mg/kg Rompun (Xylazine, Bayer AG, Leverkusen, Germany), which are used in veterinary medicine for sedation, analgesia, and muscle relaxation, in 0.2 mL of sterile pyrogen-free saline (Braun AG, Melsungen, Germany). The cecum was exposed through a 1.0-to 1.5-cm abdominal midline incision and subjected to a ligation 6 mm from the cecal tip followed by a single puncture with a G23 needle. A small amount of stool was expelled from the punctures to ensure patency. The cecum was returned to the peritoneal cavity, and the abdominal incision was closed by layers with 5/0 prolene thread (Ethicon, Norderstedt, Germany). No antibiotics were administered in this model. For the sham-operated mice serving as controls, the cecum was mobilized but no ligation or puncture was performed. To investigate the therapeutic effect, different substances were administered by intraperitoneal injection three times daily during 3 days as indicated. Control groups received the same volume (50 -100 L) of lipopolysaccharidefree 0.9% NaCl (solvent). Arterial blood pressure was measured 24 hrs after CLP. CLP was performed blinded to the identity of the treatment group. Survival after CLP was assessed four to six times a day for Ն7 days.
To harvest tissues and organs for determination of cytokines, myeloperoxidase (MPO), and transcription factors, mice were deeply anesthetized by intraperitoneal injection of Avertin at 30 L/g of body weight (stock: 1 g of tribromethanol/620 L of 2-methyl-1-butanol, 180 L/10 mL 0.9% NaCl) 24 hrs after CLP. Peritoneal tissue and liver for electrophoretic mobility shift assay (EMSA) analysis were immediately snapfrozen in liquid nitrogen.
EMSA. Nuclear proteins from snap-frozen mouse tissues were isolated as described in detail elsewhere (24) . Nuclear extracts were assayed for NF-B binding activity using the consensus sequence 5'-AGT TGA GGG GAC TTT CCC AGG C-3'. Specificity of binding was ascertained by competition with a 160-fold molar excess of unlabeled consensus oligonucleotides. Protein-DNA complexes were separated from unbound DNA probe by electrophoresis through 5% native polyacrylamide gels containing 2.5% glycerol and 0.5ϫ trisborate ETDA buffer. Gels were dried and exposed to radiography films (Amersham Pharmacia, Freiburg, Germany) at Ϫ80°C using intensifying screens for 48 -60 hrs.
Enzyme-Linked Immunosorbent Assay. Plasma was subjected to enzyme-linked immunosorbent assay for determination of IL-1␤, IL-6, and TNF-␣ contents. Enzyme-linked immunosorbent assay kits were purchased from R&D Systems GmbH (WiesbadenNordenstadt, Germany) and used according to the manufacturer's instructions.
MPO Assay. MPO was assayed as described in detail elsewhere (25) . In brief, lung tissue was harvested immediately after the end of the experiment. Samples were snap-frozen in liquid nitrogen and stored at Ϫ80°C. The tissue was homogenized in a 0.1 M sodium phosphate buffer containing 5% hexatrimethylammoniumbromide and 5% soybean trypsininhibitor. For the release of intracellular enzymes, homogenized samples were sonicated three times for 10 secs. Subsequently, the homogenized tissues were centrifuged for 15 mins at 20,000 ϫ g. Twenty-five microliters of the supernatant were collected for MPO analysis. To this, 0.1 mL of 0.1 M sodium phosphate buffer (pH 7.0) was added containing 0.0016 mL of guaiacol and 0.0005% H 2 O 2 . The optical extinction of this solution was analyzed with a spectrophotometer (Shimazdu, UV-160, Japan) at 470 nm, 25°C, and pH 7.0. A standard curve was used to calculate the results in units per milligram of protein.
Statistical Analysis. Where indicated, values of experimental groups are given as the mean, with bars showing the SEM. The means of groups were compared by Student's t-test. When Kaplan-Meier estimates of group survival distributions are shown, the log-rank test was used to compare two or more survival distributions; the given results are presented as mean survival time in hours and SEM, as in most groups the median survival time was undefined with survival rates Ͼ50%. A result was denoted as statistically significant if the p value of its corresponding test statistic was Յ.05. All statistical computations were performed using the statistical software packages R (version 1.8; R Development Core Team) and GraphPad Prism (version 4.02; GraphPad Software).
RESULTS

Cholinesterase Inhibition Improves Survival in Experimental Sepsis and Is as
Effective as Nicotinic Stimulation. Administration of nicotine can activate the cholinergic anti-inflammatory pathway and protect against lethal septic shock (11). We therefore hypothesized that systemic treatment with the cholinesterase inhibitor physostigmine would be able to activate the cholinergic anti-inflammatory pathway and improve survival in experimentally induced sepsis. Immediately after CLP-induced sepsis, mice were treated with either the cholinergic agonist nicotine (400 g/kg) or the cholinesterase inhibitor physostigmine (80 g/ kg) three times daily for 3 days. Treated animals survived significantly longer than control mice receiving the solvent (mean survival time in hours, 143.1 Ϯ 11.3 and 131.8 Ϯ 12.6 vs. 69.1 Ϯ 12.3, respectively; p log-rank Ͻ .001) (Fig. 1) . Notably, after survival of the initial phase, there were no further dropouts within an observation period of 7 days, indicating a Figure 1 . Physostigmine and nicotine treatment protect against septic shock induced by cecal ligation and puncture (CLP). Mice received repeated intraperitoneal injections of physostigmine, nicotine, or solvent (lipopolysaccharide-free 0.9% NaCl) directly after CLP. Physostigmine-treated animals received an initial 80 g/kg physostigmine and than 80 g/kg physostigmine three times daily for 3 days. Nicotine-treated animals received 400 g/kg nicotine three times daily for 3 days. Cholinesterase inhibition protected the mice against lethal septic shock as effectively as nicotinic cholinergic stimulation compared with solventtreated controls. Three independent experiments are summarized, n ϭ 21 in each group. Solid line, solvent; dashed line, physostigmine; dotted line, nicotine. p log-rank Ͻ .001. true resolution of sepsis rather than delayed dying kinetics.
Since the potential of cholinesterase inhibition by physostigmine to improve survival in a magnitude comparable to nicotine was established, we sought to further improve the response by increasing the dose of physostigmine. Mice that were administered physostigmine at 80 g/kg after CLP survived slightly longer than animals receiving a doubled dose of 160 g/kg (mean survival time in hours, 138.9 Ϯ 11.4 and 124.0 Ϯ 13.7, respectively). Overall survival analysis showed that treated animals survived significantly longer than control mice receiving the solvent (mean survival time in hours, 80.4 Ϯ 13.8; p log-rank Ͻ 0.01).
Cholinesterase Inhibition Reduces NF-B Activation, Proinflammatory Mediator Generation, and Pulmonary Accumulation of Neutrophils. CLP-induced sepsis led to a strong increase in NF-B binding activity assayed with EMSA in liver and peritoneal tissue. In contrast, in mice treated with the cholinesterase inhibitor physostigmine (80 g/kg) following CLP we found no difference in NF-B binding activity compared with sham-operated mice. This finding suggests that the suppression of excessive NF-B activation with cholinesterase inhibition might contribute to the reduced mortality (Fig. 2, A and B) .
As hypothesized for the activation of the cholinergic anti-inflammatory pathway by cholinesterase inhibition, plasma concentrations of the proinflammatory cytokines TNF-␣ (86.9 Ϯ 3.3 pg/mL vs. 35.6 Ϯ 2.3 pg/mL, p Յ .001), IL-1␤ (452.3 Ϯ 16.6 pg/mL vs. 159.6 Ϯ 4.9 pg/mL, p Յ .001), and IL-6 (521.1 Ϯ 11.2 pg/mL vs. 404.2 Ϯ 9.3 pg/mL, p Յ .001) were also significantly reduced in animals treated with physostigmine compared with control animals (Fig. 2C) .
MPO activity was determined in pulmonary tissue; this is indicative of neutrophil leukocyte invasion and is another symptom of a systemic inflammatory response. In accordance with results shown previously, MPO activity was significantly reduced in neostigmine-treated animals compared with controls (0.2 Ϯ 0.03 units/mg vs. 0.31 Ϯ 0.03 units/mg, p ϭ .028) and was not different than the levels found in animals treated with physostigmine (0.16 Ϯ 0.03 units/mg, p ϭ .282) or sham-operated animals (0.18 Ϯ 0.03 units/mg, p ϭ .741) (Fig. 2D) .
Hypotension is another marker of septicemia. From baseline measurements of 111 Ϯ 16.5 mean arterial pressure before CLP, there was a significantly more pronounced decrease in control animals than physostigminetreated animals 24 hrs after CLP (74 Ϯ 19.5 vs. 96 Ϯ 17.3, p ϭ .015).
Central Cholinesterase Inhibition Is Not Required for Protection Against Experimental Sepsis. It has been shown that the cholinergic anti-inflammatory pathway can be activated by direct stimulation of the vagus nerve, peripheral stimulation of the ␣7 nAChR, or central stimulation of the central muscarinic M1 acetylcholine receptors. To investigate whether central cholinergic activation is necessary, we compared treatment with physostigmine, which crosses the blood-brain barrier, to treatment with neostigmine, which does not and, thus, only acts in the periphery (26) .
Animals treated with either the standard dose of physostigmine (80 g/kg) or neostigmine (80 g/kg) showed significantly improved survival compared with control animals (mean survival time in hours, 119.4 Ϯ 13.7 and 127.1 Ϯ 12.8 vs. 80.0 Ϯ 13.9, respectively; p log-rank ϭ .03) (Fig. 3) . Therefore, peripheral stimulation of cholinergic receptors is sufficient to confer protection against experimental sepsis, and the additional central component of cholinesterase inhibition by physostigmine is not needed to achieve the observed activation of the anti-inflammatory pathway.
Delayed Administration of Cholinesterase Inhibitors. Here we have shown that cholinesterase inhibition significantly improves survival if administered directly after induction of sepsis by CLP. To determine whether this therapeutic approach is protective when sepsis is readily established, we administered physostigmine with a delay of 6 hrs after CLP. Even though survival was reduced in the delayed treatment group compared with immediate treatment, there was still considerable, although not statistically significant (mean survival time in hours: 115.6 Ϯ 13.4 vs. 79.1 Ϯ 13.9; p log-rank ϭ .057), protection compared with the control group (Fig. 4) .
DISCUSSION
Here we report that activation of the cholinergic anti-inflammatory pathway by systemic cholinesterase inhibition helps to control overwhelming inflammation and significantly improves survival. That this pathway can be used for protection against experimental sepsis has been shown by various groups (9, 11-15, 17, Figure 2 . Nuclear factor (NF)-B activation, cytokine production, and pulmonary myeloperoxidase concentrations after cecal ligation and puncture (CLP) are reduced by cholinesterase inhibition. A, 24 hrs after sham operation or CLP, peritoneal and liver tissues were harvested for isolation of nuclear proteins for electrophoretic mobility shift assay (EMSA). NF-B binding activity was reduced in animals that underwent cholinesterase inhibition. Experiments were repeated twice with similar results, and one representative EMSA for NF-B binding activity is shown. The NF-B complex is indicated by an arrow. B, optical densities of NF-B bands were analyzed by a calibrated imaging densitometer and normalized to sham-operated animals (n ϭ 5 per group; *p Յ 0.05). C, 24 hrs after CLP, serum was collected from physostigmine-treated (80 g/ kg) and control mice, and cytokine concentrations were measured by enzyme-linked immunosorbent assay. Concentrations of proinflammatory cytokines were significantly reduced after physostigmine treatment (mean Ϯ SEM; filled bars, control mice; open bars, physostigmine-treated mice; n ϭ 7 for each group; **p Յ .01). D, MPO activity, indicative of neutrophil invasion, was determined in lung tissue at the end of the experiment. In solvent-treated control animals, there was significantly higher MPO activity than in sham-operated animals or animals treated with neostigmine or physostigmine (mean Ϯ SEM; n ϭ 10 for each group; *p Յ .05; **p Յ .01). 18 ), most recently in the treatment of experimental inflammatory bowel disease (27) and pancreatitis (16) .
To determine the efficacy of cholinesterase inhibition in improving survival we performed CLP, which causes lethal peritonitis by polymicrobial infection and is a relevant animal model for human sepsis (5, 11, 23) . We found a significant reduction in NF-B binding activity by cholinesterase inhibition. This corresponds with findings reported by Wang et al. (11) , who showed a similar blunting of the NF-B pathway upon activation of the cholinergic anti-inflammatory pathway through nicotinic stimulation. In mice expressing a defective receptor for advanced glycation end-products (RAGE Ϫ/Ϫ) that display increased survival after CLP, we previously also showed reduced NF-B-activation (23) . Most inflammatory signals indeed converge at the activation of the NF-B pathway, and NF-B has been shown to play a central role in modulating mortality in experimental (23, 28) and clinical (29) sepsis. Thus, the observed down-regulation of NF-B transactivation activity upon cholinesterase inhibition is potentially an underlying reason for the improved survival in our model.
Furthermore, cholinesterase inhibition significantly reduced pulmonary neutrophil invasion and production of TNF-␣, IL-1␤, and IL-6, although these proinflammatory cytokines were still detectable in considerable concentrations. However, complete neutralization of TNF-␣ after CLP has been shown to increase mortality (20, 22) . Activation of the cholinergic anti-inflammatory pathway by cholinesterase inhibition might therefore sufficiently reduce serum cytokine concentrations to sublethal levels, preventing shock and death. As well, residual levels of these cytokines are probably sufficient and necessary for clearance of bacterial infections.
Cholinesterase inhibition was as effective in improving survival in CLPinduced sepsis as the established method of direct stimulation of the nAChR by nicotine (11, 15) . Treatment with the peripherally acting neostigmine as well as treatment with the both centrally and peripherally acting physostigmine conferred resistance to lethal sepsis, indicating that peripheral cholinesterase inhibition is sufficient to achieve the observed protection. As peripheral muscarinic cholinergic stimulation is not involved in the activation of the cholinergic anti-inflammatory pathway (18) , the mechanism is most likely mediated by stimulation of the peripheral nAChR. To date, the precise mechanisms that control the cholinergic anti-inflammatory pathway are not known. It can be speculated that the central muscarinic network influences the vagal cholinergic anti-inflammatory response (7). The fact that no differences were observed in our study between central and peripheral stimulation might be due to maximal activation of the pathway's effector arm.
Recently, Akinci et al. (30) failed to see effects of neostigmine (100 g/kg) in a mouse model of endotoxin-induced septic shock, while at higher doses (300 g/kg) mortality was increased despite a moderate decrease in inflammation. This contradicts our findings, for reasons that remain elusive.
A trend toward a protective effect was seen in our study when treatment was delayed 6 hrs after CLP, suggesting a reasonable window of time for the treatment of sepsis. However, probably due to a small case number in our study, this did not reach statistical significance. When treatment was delayed beyond 6 hrs, no trend to a reduction in mortality could be achieved (data not shown). This contradicts the findings of Wang et al. (11) , who demonstrated that nicotine treatment could be delayed for 24 hrs after sepsis in a similar experimental model. This increased lethality in our experimental setup might be explained at least in part by the use of antibiotics (primaxin at 0.5 mg/kg) by Wang et al., whereas our animals did not receive antibiotic treatment. Also, mice strains were used (BALB/c vs. C57/Bl6) that may be different in susceptibility to peritonitis induced by CLP.
Our study is limited by the use of ketamine as an anesthetic for the CLP procedure, even though it has been successfully used in other studies on the cholinergic anti-inflammatory pathway (11, 17) . Ketamine is a noncompetitive inhibitor of the nAChR (31) that might leave the receptor unresponsive to acetylcholine elevations induced by cholinesterase inhibitors. However, in our study, animals received only a single dose of ketamine, and the elimination half-time of ketamine is approximately 3 hrs. This might have attenuated the effects observed for the treatment with cholinesterase inhibitors, and these effects might have been even more pronounced if anesthesia had been achieved by a different drug.
Cholinesterase inhibition might be considered as a therapeutic concept not only in sepsis but also in other inflammatory diseases, such as pancreatitis or ulcerative colitis. Further studies are required on potential side effects that might include gastrointestinal spasm, bradycardia, and hypotension as well as salivation and sweating.
CONCLUSION
We demonstrate that pharmacologic cholinesterase inhibition with physostigmine and neostigmine improves survival in murine experimental sepsis consistent with activation of the cholin- After cecal ligation and puncture (CLP) was performed, treatment was delayed by 6 hrs. This regimen could reduce the lethality of CLPinduced sepsis compared with solvent-treated animals, although this did not reach statistical significance. Three independent experiments are summarized, n ϭ 21 in each group. Solid line, solvent; dashed line, physostigmine 80 g/kg after 6 hrs; p log-rank ϭ .057. ergic anti-inflammatory pathway. Our findings provide a rationale for further exploration and may have important implications in the development of new treatment strategies.
